Wyse, PhD, J. J., Morasco, PhD, B. J., Dobscha, MD, S. K., Demidenko, BS, M. I., Meath, MPH, T. H. A. and Lovejoy, PhD, MPH, T. I. (2018) “Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified”, Journal of Opioid Management, 14(4), pp. 295–303. doi: 10.5055/jom.2018.0461.